文摘
A new series of P-glycoprotein (Pgp)-dependent multidrugresistance (MDR) inhibitors having a N,N-bis(cyclohexanol)aminescaffold have been designed, following the frozen analog approach.With respect to the parent flexible molecules, the new compounds showimproved potency and efficacy. Among them, compound 1d, onanthracycline-resistant erythroleukemia K562 cells, is able to completelyreverse Pgp-dependent MDR at low nanomolar concentration.